同济大学学报（医学版）2012，Vol.33Issue(4)：57-62,6.DOI:10.3969/j.issn1008-0392.2012.04.013
长春瑞宾单药与长春瑞宾联合卡铂治疗≥75岁的老年晚期非小细胞肺癌患者的临床研究
Vinorelbine versus vinorelbine-carboplatin in treatment of elderly patients with advanced non-small cell lung cancer
李爱武 1周彩存 1徐建芳 1任胜祥 1陈晓霞 1朱韧1
作者信息
- 1. 同济大学附属肺科医院肿瘤科,上海200433
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of vinorelbine versus vinorelbine-carboplatin in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods The clinical characteristics, treatment strategies and survival features of 51 elderly patients( ≥ 75years)with NSCLC admitted between January 2006 to December 2008 were retrospectively analyzed. Results The mean therapeutic cycles of vinorelbine and vinorelbine-carboplatin group were 1.9 and 2.3 respectively (P = 0. 295 ). Among 21 and 14 efficacy-evaluable patients in each group, the partial remission (PR) rates were 9.5% and 28.6% respectively(P = 0.191); the median survival time were 7.2 (95% CI; 4.9, 9.5) months and 9. 3 (95%CI: 4.3, 15.7) months; and the 1,2-year survival rates were 39.7% ,10% and 45.0% ,13% (Log Rank P =0. 679). Cox regression analysis shows that patients with performance status (PS) -2 and severe comorbidities had a poorer prognosis than those with PS =0 - 1 and mild comorbidities (P = 0. 061, 0. 183). No grade 4 hematological toxicity was found, the grade 3 hematological toxicities of two groups were neutropenia (6. 5%, 15. 0%), leukopenia(6.5% ,10.0% ) , anemia(6. 5% ,5. 0% ) and thrombopenia (3. 2% ,5. 0% ). Only grade 1-2 non-hematological toxicities were recorded. And no differences of toxicity profiles were found between the two groups. Conclusion Compared with single agent, vinorelbine-carboplatin seems to be a feasible treatment option with a favorable toxicity profile for elderly ( ≥75years) patients with advanced NSCLC. PS status and comorbidities may be the most important prognostic factors.关键词
老年/非小细胞肺肿瘤/长春瑞宾/卡铂Key words
elderly/ non-small cell lung cancer/ vinorelbine/ carboplatin分类
医药卫生引用本文复制引用
李爱武,周彩存,徐建芳,任胜祥,陈晓霞,朱韧..长春瑞宾单药与长春瑞宾联合卡铂治疗≥75岁的老年晚期非小细胞肺癌患者的临床研究[J].同济大学学报（医学版）,2012,33(4):57-62,6.
